Development of antibodies to the nonstructural protein NS1 of parvovirus B19 during acute symptomatic and subclinical infection in pregnancy: Implications for pathogenesis doubtful

被引:0
作者
Searle, K [1 ]
Schalasta, G [1 ]
Enders, G [1 ]
机构
[1] Inst Virol Infektiol & Epidemiol Ev, D-70193 Stuttgart, Germany
关键词
nonstructural protein; antibodies; parvovirus;
D O I
10.1002/(SICI)1096-9071(199811)56:3<192::AID-JMV3>3.0.CO;2-2
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
At present little is known about the mechanisms influencing the course and severity of parvovirus B19 infection. Antibodies to the parvovirus nonstructural protein NS1 were reported in patients with parvovirus-associated arthritis and those with persisting infection but not in those without complications, suggesting a potential involvement of NS1 or anti-NS? antibodies in pathogenesis. The immune response to NS1 was examined retrospectively in 33 pregnant women with acute parvovirus B19 infection, 14 of whom experienced symptomatic infection and 19 in whom the infection was subclinical. Antibodies to NS1 were found in 15 (45%) of the women, seven with symptomatic and eight with subclinical infection. No association was found between the development of anti-NS1 antibodies and the occurrence of fetal complications. Of the seven cases in which fetal complications were observed, anti-NS1 antibodies were detected in only three. The finding that an immune response to NS1 can also be demonstrated in patients with asymptomatic infection suggests that anti-NS1 antibodies do not appear to represent a marker for an altered or severe course of infection in pregnant women or to contribute significantly to pathogenesis. Since anti-NS1 antibodies first become detectable at least six weeks postinfection, their presence can be used to exclude acute infection in patients with unclear serology or be used to aid differential diagnosis of rashlike illnesses. J. Med. Virol. 56: 192-198, 1998. (C) 1998 Wiley-Liss, Inc.
引用
收藏
页码:192 / 198
页数:7
相关论文
共 17 条
  • [1] ANDERSON MJ, 1983, LANCET, V1, P1378
  • [2] CONGENITAL ANEMIA AFTER TRANSPLACENTAL B19 PARVOVIRUS INFECTION
    BROWN, KE
    GREEN, SW
    DEMAYOLO, JA
    BELLANTI, JA
    SMITH, SD
    SMITH, TJ
    YOUNG, NS
    [J]. LANCET, 1994, 343 (8902) : 895 - 896
  • [3] Life-threatening parvovirus B19-associated myocarditis and cardiac transplantation as possible therapy:: Two case reports
    Enders, G
    Dötsch, J
    Bauer, J
    Nützenadel, W
    Hengel, H
    Haffner, D
    Schalasta, G
    Searle, K
    Brown, KE
    [J]. CLINICAL INFECTIOUS DISEASES, 1998, 26 (02) : 355 - 358
  • [4] ENDERS G, 1998, TOPLEY WILSONS MICRO, P890
  • [5] OBSERVATIONAL STUDY OF EFFECT OF INTRAUTERINE TRANSFUSIONS ON OUTCOME OF FETAL HYDROPS AFTER PARVOVIRUS B19 INFECTION
    FAIRLEY, CK
    SMOLENIEC, JS
    CAUL, OE
    MILLER, E
    [J]. LANCET, 1995, 346 (8986): : 1335 - 1337
  • [6] CHRONIC PARVOVIRUS B19 INFECTION AND SYSTEMIC NECROTIZING VASCULITIS - OPPORTUNISTIC INFECTION OR ETIOLOGIC AGENT
    FINKEL, TH
    TOROK, TJ
    FERGUSON, PJ
    DURIGON, EL
    ZAKI, SR
    LEUNG, DYM
    HARBECK, RJ
    GELFAND, EW
    SAULSBURY, FT
    HOLLISTER, JR
    ANDERSON, LJ
    [J]. LANCET, 1994, 343 (8908) : 1255 - 1258
  • [7] HALL SM, 1990, BMJ-BRIT MED J, V300, P1166
  • [8] PATTISON JR, 1981, LANCET, V1, P664
  • [9] POBLOTZKI A, 1995, J GEN VIROL, V76, P519
  • [10] POBLOTZKI A, 1995, J INFECT DIS, V172, P1356